Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;186(4):726-728.
doi: 10.1111/bjd.20885. Epub 2022 Jan 20.

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting

K A Papp  1   2 , M J Gooderham  1   3   4 , L E Albrecht  1   5   6 , M-A Raymond  7 , C W Lynde  1   8
Affiliations

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting

K A Papp et al. Br J Dermatol. 2022 Apr.

Abstract

PubMed Disclaimer

Figures

Figure 1
Figure 1
Impact of adding methotrexate to an adalimumab therapy in patients with psoriasis. (a) Satisfaction questions, response choices and satisfaction with treatment at baseline and weeks 8, 16 and 24 for investigator assessment and patient self‐assessment; satisfaction achieved defined as highly satisfied or completely satisfied. (b) PASI responses at weeks 8, 16 and 24. (c) PGA clear or minimal; DLQI score of 0 or 1 at weeks 8, 16 and 24. (d) Adalimumab concentration at weeks 8, 16 and 24: PASI responses, PGA clear or minimal response, and DLQI score of 0 or 1 response. Bars show 95% CIs, except for adalimumab concentrations, shown with SD. Proportions are shown for the nonresponder imputation analysis. Similar results were obtained with a last‐observation‐carried‐forward analysis, used for sensitivity. PsO, psoriasis; CI, confidence interval; PASI, Psoriasis Area Severity Index; PGA, Physician’s Global Assessment; DLQI, Dermatology Life Quality Index.
See this image and copyright information in PMC

References

    1. Leonardi C, Kimball A, Papp K et al. Efficacy and safety of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with psoriasis: 76‐week results from a randomised, double‐blind, placebo‐controlled trial (PHOENIX 1). Lancet 2008; 371:1665–74. - PubMed
    1. Menter A, Tyring S, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106–15. - PubMed
    1. Tanaka Y, Mimori T, Yamanaka H et al. Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic‐naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. Mod Rheumatol 2019; 29:572–80. 10.1080/14397595.2018.1500979. - DOI - PubMed
    1. Abbvie. A study of subjects with psoriatic arthritis to investigate the effectiveness of adalimumab introduction compared with methotrexate dose escalation (CONTROL). ClinicalTrials.gov identifier: NCT02814175.
    1. Papp K, Gulliver W, Lynde C et al.; Canadian Psoriasis Guidelines Committee . Canadian guidelines for the management of plaque psoriasis: overview. J Cut Med Surg 2011; 15:210–19. 10.2310/7750.2011.10066. - DOI - PubMed

Grants and funding